drugset
drugset / Trial / NCT05571540

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

NCT05571540 ↗

Phase 1/2 Withdrawn Kunming Hope of Health Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of LstCAR019 injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).

Timeline

Start
2022-10-01
Primary completion
2024-01-31
Completion
2024-10-31

Outcome

Outcome not reported

Stopped: “The PI decides to stop.”

Drugs

EvaluationDrugModalityDoseRoute
Subject LstCAR019 Cell therapy 1e+06 cells/kg Intravenous
Subject LstCAR019 Cell therapy 2e+06 cells/kg Intravenous
Subject LstCAR019 Cell therapy 5e+06 cells/kg Intravenous

Indications

B-cell acute lymphoblastic leukemia